What question did this study set out to answer?

To evaluate the efficacy of dual immune checkpoint blockade in patients with melanoma brain metastases.

November 1, 2025Neuro-OncologyOpen Access

Ctim-28. Intracranial and Systemic Efficacy of Dual Immune Checkpoint Blockade (Nivolumab and Ipilimumab) in Melanoma Brain Metastases: A Meta-Analysis

View Full Paper

Ask AI

Bookmark

To evaluate the efficacy of dual immune checkpoint blockade in patients with melanoma brain metastases.
Conducted a meta-analysis of studies from PubMed/Medline, Cochrane Library, and conference proceedings.
Analyzed overall survival, progression-free survival, and response rates across 26 studies with 2,307 patients.
Utilized random-effects models for pooled outcomes and performed subgroup analysis and meta-regression.
Pooled overall survival was 21.3 months; first-line treatment showed 23.1 months versus 18.1 months for non-first-line.
Progression-free survival averaged 7.0 months; first-line treatment achieved 7.1 months compared to 5.0 months for non-first-line.
Average intracranial response rate was 42% and extracranial response rate was 34%, indicating high treatment effectiveness.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Meta-analysis reveals improved progression-free survival in patients with melanoma brain metastases treated with dual checkpoint inhibitors, indicating first-line efficacy.

Cite This Study

Sarfraz et al. (2025) studied this question.

synapsesocial.com/papers/6925436cc0ce034ddc3585b8 https://doi.org/10.1093/neuonc/noaf201.0485

View Full Paper

Ask AI

Bookmark

Implication

Meta-analysis reveals improved progression-free survival in patients with melanoma brain metastases treated with dual checkpoint inhibitors, indicating first-line efficacy.

Ctim-28. Intracranial and Systemic Efficacy of Dual Immune Checkpoint Blockade (Nivolumab and Ipilimumab) in Melanoma Brain Metastases: A Meta-Analysis

Key Points

Discussion

Implication

Cite This Study

Ctim-28. Intracranial and Systemic Efficacy of Dual Immune Checkpoint Blockade (Nivolumab and Ipilimumab) in Melanoma Brain Metastases: A Meta-Analysis

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider